MannKind Corporation (MNKD)
News
| May 26 | Shorter Timeframe, More Risky |
| May 24 | Shorter Timeframe, More Risky Fool |
| May 24 | Bull Case for Mannkind Fool |
| May 24 | 2 Promising Medical Companies Near Their Lows |
| May 23 | Why Mannkind Has Long-Term Value |
| May 23 | $mnkd 2014 will be al's year where tgis will be global . by Streetbull |
| May 22 | MANNKIND CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submissi... |
| May 21 | Wall Street's Buy List Fool |
| May 18 | Biotech Industry Booming in 2012 Marketwire |
| May 17 | MANNKIND CORP Financials |
| May 10 | 3 Stocks Sink to 52-Week Lows http://stks.co/3lto My story via @TheStreet $DGIT $MNKD $WIN #52WeekLow by azendrian |
| May 08 | great day for most biotechs on the watchlist $ONTY $ARNA $CTIC $ASTX $EXEL $MNKD $ECYT by swingtrades99 |
| Apr 30 | Tolero and $MNKD Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors. http://stks.co/3ZpY by abubnic |
| Apr 23 | $MNKD Could be a good swing trade- I got a first position at 2.12 by ballhawker |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
MannKind Corporation, based in Valencia, California, is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. The company, while technically founded in February 1991, took its present form in 2003 as a merger of three companies owned by Alfred E. Mann, named after its founder in an attempt at humor. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone Inhaler, upon which was developed its lead product, Afrezza, which was under FDA review. Alfred Mann is chairman of the board and chief executive officer. Mann has invested approximately $900 million in his company.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). MannKind Corporation is down 55.15% over the last year vs S&P 500 Total Return up 0.88%, BioMarin Pharmaceutical up 35.64%, and Sunesis Pharmaceuticals up 5.32%.
- MNKD Total Returns
- ^SPXTR Total Returns
- BMRN Total Returns
- SNSS Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these MNKD related companies
Pro Strategies Featuring MNKD
Did MannKind Corporation make it into our Pro Portfolio Strategies?
MNKD Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other MNKD Resources
- Wiki Page
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MNKD | 1.83 | -0.01 | -0.54% | 306.47M |
| MNI | 2.19 | -0.02 | -0.91% | 187.05M |
| MNE | 15.25 | +0.14 | +0.89% | |
| MNDO | 1.70 | -0.01 | -0.58% | 31.84M |
| MKTX | 32.33 | -0.11 | -0.34% | 1.164B |
| MKTG | 10.34 | -0.01 | -0.10% | 490.53M |
| MKTAY | 33.29 | -0.83 | -2.43% | 4.549B |
| MKSI | 26.17 | -0.26 | -0.98% | 1.375B |
| MKL | 434.25 | -1.00 | -0.23% | 4.191B |
| MKC | 56.57 | -0.77 | -1.34% | 7.501B |
